Julia Blanco

2 months ago | nature.com | Daniel Perez-Zsolt |Edurne García-Vidal |Gerardo Ceada |Dàlia Raïch-Regué |Laia Soler |Sonia Guil | +11 more

AbstractPlitidepsin is an antitumoral compound safe for treating COVID-19 that targets the translation elongation factor eEF1A. Here we detect that plitidepsin decreases de novo cap-dependent translation of SARS-CoV-2 and non-viral RNAs but affects less than 13% of the host proteome, thus preserving cellular viability.

Mar 20, 2024 | nature.com | Marco Brustolin |Nuria Pedreno-Lopez |Jordi Rodon |Víctor Urrea |Edwards Pradenas |Anna Pons-Grífols | +10 more

AbstractSafe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels.

May 2, 2023 | frontiersin.org | Peter Hunt |Julia Blanco |Souheil-Antoine Younes

Liting Yan1,2*, Kaiju Xu1,2, Qing Xiao3, Lin Tuo1,2, Tingting Luo1,2, Shuqiang Wang1,2, Renguo Yang1,2, Fujie Zhang3* and Xingxiang Yang1,2* 1Department of Infectious Disease, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China 2Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China 3Clinical and Research Center for Infectious Diseases, Beijing Ditan Hospital, Beijing, China Highly active...